WAVE Life Sciences (NASDAQ:WVE) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

WAVE Life Sciences (NASDAQ:WVE) issued its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03, FiscalAI reports. The firm had revenue of $13.16 million for the quarter, compared to analysts’ expectations of $4.51 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• WVE-007 obesity program advanced with Phase IIa monotherapy and tirzepatide-combination trials underway, while a post-incretin maintenance study remains on track to begin in Q4 2026. Management expects higher-baseline-adiposity patients and multiple dosing to support progress toward the 5% one-year weight-loss regulatory benchmark.
• The company reported encouraging clinical durability and body-composition findings for WVE-007, including reductions in visceral and total fat with lean-mass preservation, and expects additional 600 mg Phase I data in Q4 to inform potency, duration, safety, and dosing frequency.
• FDA discussions supported a potentially efficient single two-year registrational trial for WVE-006 in AATD, with a one-year interim analysis that could support accelerated approval based on biomarkers. The company also said the FDA was comfortable with its LC-MS assay for measuring M-AAT and Z-AAT.
• Wave plans to submit a CTA for its second RNA-editing candidate, WVE-008 for PNPLA3 I148M liver disease, in 2026 and intends to use pre-genotyped populations to accelerate first-in-human enrollment.
• Operating expenses and net loss increased year over year as Wave invested in its expanding clinical pipeline; third-quarter net loss was $61.9 million versus $53.9 million a year earlier. The company ended the quarter with $431 million in cash and securities, projected to fund operations into Q3 2028, plus a $12 million GSK milestone expected in Q4.

WAVE Life Sciences Stock Up 3.5%

Shares of NASDAQ:WVE traded up $0.13 on Thursday, reaching $3.77. 1,295,007 shares of the company’s stock were exchanged, compared to its average volume of 3,710,145. The business’s 50-day moving average is $4.13 and its two-hundred day moving average is $7.60. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73. The firm has a market capitalization of $742.77 million, a price-to-earnings ratio of -3.46 and a beta of -1.43.

Insider Transactions at WAVE Life Sciences

In other news, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total transaction of $67,183.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi L. Wagner sold 7,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. This trade represents a 13.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 23,564 shares of company stock valued at $132,476. Insiders own 24.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on WVE. Mizuho cut their price target on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. William Blair assumed coverage on WAVE Life Sciences in a research note on Friday, October 16th. They set an “outperform” rating on the stock. LADENBURG THALM/SH SH started coverage on shares of WAVE Life Sciences in a research note on Thursday, October 1st. They set a “buy” rating and a $10.00 price objective for the company. JPMorgan Chase & Co. started coverage on WAVE Life Sciences in a report on Wednesday, September 23rd. They issued a “neutral” rating on the stock. Finally, Wall Street Zen downgraded shares of WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 1st. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, WAVE Life Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $20.89.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.